BAX and B-cell chronic lymphocytic leukemia: In contrast, ibrutinib treatment with ALA, melatonin, and resveratrol significantly up-regulates the expression of BAX (range 2-fold to 3.4-fold) and CASP3 (2-fold to 3.9-fold) in CLL cybrid cells.